US4851232A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug delivery system with means for obtaining desirable in vivo release rate pattern
Assignee: Alza Corp
•
Filing: 1987-06-08
•
Granted: 1989-07-25
•
Expires: 2007-06-08
Abstract
Abstract A delivery device is disclosed for delivering a beneficial drug to a biological environment of use. The device comprises a hydrogel reservoir containing tiny pills. The tiny pills comprise a wall surrounding a drug core.
Inventors
- 👤 John Urquhart
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 13:17
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065; A61K9/20; A61K9/2072; A61K9/2077
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
105 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a reservoir comprising a pharmaceutically acceptable hydroxypropylmethylcellulose; and, (b) a plurality of tiny pills housed in the reservoir, the tiny pills comprising: (1) a core of a beneficial drug; and, (2) a wall comprising in at least a part a drug release rate controlling cellulosic polymer comprising an acetyl content of 21 to 44.8% that surrounds the core of the beneficial drug and releases the drug when the device is in use in the environment of use.
Claim 2
Dependent Claim
105 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a reservoir comprising a pharmaceutically acceptable hydroxypropylmethylcellulose; and, (b) a plurality of tiny pills housed in the reservoir, the tiny pills comprising: (1) a core of a beneficial drug; and, (2) a wall comprising in at least a part a drug release rate controlling cellulosic polymer comprising an acetyl content of 21 to 44.8% that surrounds the core of the beneficial drug and releases the drug when the device is in use in the environment of use.
Claim 3
Dependent Claim
64 words
The drug delivery device for the controlled delivery of the beneficial drug according to claim 1, wherein the environment of use is the gastrointestinal tract, the drug is a beneficial gastrointestinal administrable drug, and the hydroxypropylmethylcellulose comprises a viscosity of from 3 to 258,000, a degree of polymerization of from 48 to 2,000 and a number average molecular weight of from 9,200 to 350,000.
Claim 4
Dependent Claim
89 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a reservoir comprising a hydroxypropylmethylcellulose; and, (b) a multiplicity of tiny pills housed in the reservoir, the tiny pills comprising: (1) a dosage unit amount of a beneficial drug; (2) a wall comprising in at least a part etyl cellulose that surrounds the beneficial drug and releases the beneficial drug when the device is in operation in the environment of use.
Claim 5
Dependent Claim
89 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a reservoir comprising a hydroxypropylmethylcellulose; and, (b) a multiplicity of tiny pills housed in the reservoir, the tiny pills comprising: (1) a dosage unit amount of a beneficial drug; (2) a wall comprising in at least a part etyl cellulose that surrounds the beneficial drug and releases the beneficial drug when the device is in operation in the environment of use.
Claim 6
Dependent Claim
91 words
The drug delivery device for the controlled delivery of a beneficial drug according to claim 3, wherein the environment of use is the gastrointestinal tract the drug is a beneficial gastrointestinal administrable drug, the delivery device is admittted orally into the gastrointestinal tract, and the hydroxypropylmethylcellulose comprises a viscosity of from 3 to 258,000 centipoises, a degree of polymerization of from 48 to 2,000, a number average molecular weight of from 9,200 to 350,000, and exhibits a 2 to 50 fold volume increase in the fluid environment of the gastrointestinal tract.
Claim 7
Dependent Claim
127 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a matrix shaped and sized for oral admittance into the environment of use, the matrix comprising a pharmaceutically acceptable non-toxic hydroxypropylcellulose that absorbs fluid from the gastrointestinal tract, expands and exhibits a 2 to 50 fold volume increase and comprises a hydroxypropyl content of 7 to 16%; and, (b) a plurality of tiny pills dispersed in the matrix, the tiny pills comprising: (1) a dosage amount of a beneficial drug; and, (2) a wall that surrounds the beneficial drug, the wall comprising in at least a part of cellulosic polymer comprising an acetyl content of from 21 to 44.8%.
Claim 8
Dependent Claim
127 words
A drug delivery device for the controlled delivery of a beneficial drug to an environment of use over a prolonged period of time, the delivery device comprising: (a) a matrix shaped and sized for oral admittance into the environment of use, the matrix comprising a pharmaceutically acceptable non-toxic hydroxypropylcellulose that absorbs fluid from the gastrointestinal tract, expands and exhibits a 2 to 50 fold volume increase and comprises a hydroxypropyl content of 7 to 16%; and, (b) a plurality of tiny pills dispersed in the matrix, the tiny pills comprising: (1) a dosage amount of a beneficial drug; and, (2) a wall that surrounds the beneficial drug, the wall comprising in at least a part of cellulosic polymer comprising an acetyl content of from 21 to 44.8%.
Claim 9
Dependent Claim
34 words
The drug delivery device for the controlled delivery of a beneficial drug according to claim 5, wherein the reservoir releases the tiny pills over time and tiny pills release the beneficial drug over time.
Claim 10
Dependent Claim
54 words
The drug delivery device for the controlled delivery of a beneficial drug according to claim 5, wherein the environment of use is the gastrointestinal tract, the tiny pills comprise from 10 mg to 50 mg of the beneficial drug, the beneficial drug is a gastrointestinal administrable drug, and the delivery device exhibits gastric retention.
Claim 11
Dependent Claim
141 words
A drug delivery device for the controlled delivery of a beneficial gastrointestinal administrable drug to the fluid environment of the gastrointestinal tract over a prolonged period of time, the delivery device comprising: (a) a matrix adapted for oral admittance into the gastrointestinal tract, the matrix comprising a pharmaceutically acceptable nontoxic hydroxypropylcellulose that absorbs fluid from the gastrointestinal tract, retains some fluid within its matrix structure, expands from 2 to 50 fold volume increase and comprises a hydroxypropyl content of 7 to 16%; and, (b) a plurality of tiny pills dispersed throughout the matrix, the tiny pills comprising: (1) a dosage amount of a beneficial drug; and, (2) a wall that surrounds the beneficial drug, the wall comprising at least in part ethyl cellulose that releases the beneficial drug when the delivery device is in use in the gastrointestinal tract over time.
Claim 12
Dependent Claim
141 words
A drug delivery device for the controlled delivery of a beneficial gastrointestinal administrable drug to the fluid environment of the gastrointestinal tract over a prolonged period of time, the delivery device comprising: (a) a matrix adapted for oral admittance into the gastrointestinal tract, the matrix comprising a pharmaceutically acceptable nontoxic hydroxypropylcellulose that absorbs fluid from the gastrointestinal tract, retains some fluid within its matrix structure, expands from 2 to 50 fold volume increase and comprises a hydroxypropyl content of 7 to 16%; and, (b) a plurality of tiny pills dispersed throughout the matrix, the tiny pills comprising: (1) a dosage amount of a beneficial drug; and, (2) a wall that surrounds the beneficial drug, the wall comprising at least in part ethyl cellulose that releases the beneficial drug when the delivery device is in use in the gastrointestinal tract over time.
References Cited (Backward Citations)
US27107A
Cited
US2799241A
Cited
US2738303A
Cited
US2793979A
Cited
US2996431A
Cited
US2987445A
Cited
US2928770A
Cited
US3087860A
Cited
US2951792A
Cited
US3109775A
Cited
US3139382A
Cited
US3432592A
Cited
US3432593A
Cited
US3390050A
Cited
GB1182124A
Cited
US3948262A
Cited
US3870790A
Cited
US3640741A
Cited
US3865108A
Cited
US3938515A
Cited
US3867519A
Cited
US3888975A
Cited
US3811444A
Cited
US3971367A
Cited
US3993057A
Cited
US4177256A
Cited
US4178361A
Cited
US4002173A
Cited
US3992562A
Cited
US3952741A
Cited
US3952741B1
Cited
US4138344A
Cited
US4014335A
Cited
US4014334A
Cited
US4140755A
Cited
US4167558A
Cited
US4207893A
Cited
US4304591A
Cited
US4357469A
Cited
US4226849A
Cited
US4259314A
Cited
US4369172A
Cited
US4434153A
Cited
US4642233A
Cited
US4649043A
Cited
US4659558A
Cited
US4389393A
Cited
US4389393B1
Cited
US4721613A
Cited
US4578075A
Cited
US4540566A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-24 | 1993-01-23 | 1993-07-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-24 | 1997-01-23 | 1997-07-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-24 | 2001-01-23 | 2001-07-25 | $7700.00 | Window Closed / Lapsed |